Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing
Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million.
Founded in 2016, Laekna, Inc. is a science-driven, clinical-stage biotechnology company. It has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials and has initiated one clinical trial and another five clinical trials for its core products LAE002 and LAE001. Among these six clinical trials, three multi-regional clinical trials (MRCTs) are designed to address medical needs in the standard of care (SOC)-resistant cancers.
The Davis Polk corporate team included partners Xuelin (Steve) Wang, Yang Chu and Jason Xu, associates Jenny Ho and Michelle Chow and registered foreign lawyers Wentian Xie and Haiyang Zhao. Members of the Davis Polk team are based in the Hong Kong and Beijing offices.
Related Posts
Pillar Biosciences Closes $29.7 Million in Series C Financing
May 12, 2020NGS clinical cancer diagnostics company Pillar Biosciences held a Series C financing signing ceremony at its headquarters in Boston, USA, officially announcing the completion of a $29.7 million Series C financing round led by ORI Healthcare Fund, which raised Series A funding. The financing will accelerate the expansion of Pillar’s R&D pro
” E-Tronic(Guangzhou) Technology” completes Series A financing led by Infinity Capital
E-Tronic(Guangzhou)Technology Co.，Ltd., a provider of power semiconductors and system solutions for new energy vehicles, has completed its Series A financing with a cumulative amount of over 100 million RMB. This round of financing was led by Infinity Capital, with additional investment from old shareholders Zhongnan Venture Capital and Guangzhou Development
Changyi Wins Industrial Excellence Award in Weixin Pay Application Competition
iClick Interactive Asia Group Limited (“iClick” or the “Company”), an independent online marketing and enterprise data solutions provider in China, announced that Changyi (Shanghai) Information Technology Co., Ltd (“Changyi”), a subsidiary of iClick, has been awarded a major industry accolade by Tencent’s Weixin Pay for its outstanding s
Leto Laboratories Completes Series C Financing of Over 100 Million RMB, Focusing on 0 to 1 Innovative Protein Design and Manufacturing Platform Construction
Leto Laboratories announced the completion of its Series C financing round with a funding size of over 100 million RMB. This round of financing was led by Zhongguancun Science City Corporation and followed by Infiniti Capital and HB Ventures. The round was mainly used for the clinical research of LTC004, a new-generation anti-tumor cytokine class […]
Leave a Reply